Current News - U.S.
- FDA Advisory Committee finds Data support the claim that Spiriva® Handihaler® reduces COPD Exacerbations
- Boehringer Ingelheim Announces Pivotal Phase III Data of Flibanserin in Pre-Menopausal Women with Hypoactive Sexual Desire Disorder
- Budding Videographers Vividly Portray Life with Diabetes to Mark World Diabetes Day
- Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business from Pfizer
- FDA Approves New Use for Micardis® in Cardiovascular Risk Reduction and Twynsta® as New Combination Treatment for High Blood Pressure
- View more Current News : : View the News Archive
BI Spotlight
FDA Approves New Use for Micardis® in Cardiovascular Risk Reduction and Twynsta® as New Combination Treatment for High Blood Pressure
Ridgefield, CT - October 19, 2009
Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.1
Product Sites
Job Openings
Patient Assistance Program
R&D
